Performance status, adverse features and other diseases

[Birgitta-A]

Hi all members with increases blast cells/AML,
Now National Comprehensive Cancer Network has decided about recommendations for induction chemotherapy for patients with AML and consider age 60 as a therapeutic divergence point. For older patients (>60 years) with AML, the updated guidelines recommend that patient performance status, in addition to adverse features and comorbid conditions need to be considered when selecting treatment in addition to a patient’s chronological age alone.
http://www.checkorphan.org/news/upda...ment_selection
Kind regards
Birgitta-A